drugset / Trial / NCT00366327
Study Evaluating Bifeprunox in Patients With Schizophrenia.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
An open-label extension study using a variable dose (20 to 30 mg daily) of bifeprunox to evaluate long-term safety.
Timeline
- Start
- 2007-01
- Primary completion
- 2008-03
- Completion
- 2008-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bifeprunox | Small molecule | 20 mg | — |
| Subject | Bifeprunox | Small molecule | 30 mg | — |